CAMBRIDGE, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that promising preclinical data on its first-in-class selective fibroblast growth factor receptor 4 (FGFR4) inhibitor will be presented during a late-breaking minisymposium at the 105th Annual Meeting of the American Association for Cancer Research (AACR). The oral presentation by Christoph Lengauer, Ph.D., M.B.A., Chief Scientific Officer of Blueprint, will feature in vivo efficacy data including sustained tumor regression, which highlight the potential clinical benefit for patients with hepatocellular carcinoma (HCC) with amplification or overexpression of FGF19. FGF19 is the ligand of FGFR4 and a genomic driver in HCC.
Help employers find you! Check out all the jobs and post your resume.
